RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.

It may be the last day of #ACR18 but huge interest for talk by @Deepakarao (standing room only!) Really interesting presentation showing PD-1hi CXCR5- T peripheral helper cells are significantly expanded in #SLE In particular in those with high SLEDAI and dsDNA titres

Congratulations to Dr. @VickiShanmugam, chair of ACR annual meeting planning subcommittee, @donna_hoyne VP of Education, and the whole team at ACR for putting on an outstanding conference in Chicago! #ACR18

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.

Higher number of dominant B cell receptor clones in peripheral blood predicts the development from arthralgia to active disease in rheumatoid arthritis, de Vries N #acr18

Genetic Risk score prediction in Ankylosing Spondylitis using nearly 4000 SNPs in the European cohort showed performance as good as MRI screening and may help predict development of #ankylosingsponylitis Li Z #ACR18

Case reports prompted prospective trial from Tsuji H showing evidence of combined high dose GC + TAC + CYC beneficial in idiopathic inflammatory myopathy with interstitial lung disease and MDA-5 antibody #ACR18

Genetic predisposition to lupus in women may be contributed to by X chromosomes that encode TLR7 the receptor for RNA with B cell hyperproliferation when stimulated, Pascual M #sle #lupus #tlr #ACR18

Interesting study of JAK-1 inhibitor in ankylosing spondylitis #ankylosingspondylitis #rheum #ACR18 https://t.co/c423eXEfqx

METEOR registry analysis of data from 12 countries shows association between socioeconomic status of a country and disease activity in RA patients. Biologic DMARDs when available in poorer countries had less than expected effect on disease activity, Bergstra SA #ACR18

The RISE registry showed that for 50% of RA patients, medication remained unchanged over the follow-up period, despite moderate to high disease activity. The treatment least likely to be altered was the combination of MTX and a biologic, Curtis J #ACR18

REMORA app and wearables provided data that showed positive outcomes with better information about short-lived flares, better self-awareness of the disease and better conversations and more personalised care, Dixon W #ACR18